DE602004031225D1 - 3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks - Google Patents

3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks

Info

Publication number
DE602004031225D1
DE602004031225D1 DE602004031225T DE602004031225T DE602004031225D1 DE 602004031225 D1 DE602004031225 D1 DE 602004031225D1 DE 602004031225 T DE602004031225 T DE 602004031225T DE 602004031225 T DE602004031225 T DE 602004031225T DE 602004031225 D1 DE602004031225 D1 DE 602004031225D1
Authority
DE
Germany
Prior art keywords
azaprostaglandinanaloga
reminder
oxa
lowering eye
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004031225T
Other languages
German (de)
English (en)
Inventor
David W Old
Thang D Dinh
Robert M Burk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE602004031225D1 publication Critical patent/DE602004031225D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
DE602004031225T 2003-06-02 2004-05-25 3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks Expired - Lifetime DE602004031225D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/453,207 US6734206B1 (en) 2003-06-02 2003-06-02 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
PCT/US2004/016516 WO2004108670A1 (en) 2003-06-02 2004-05-25 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure

Publications (1)

Publication Number Publication Date
DE602004031225D1 true DE602004031225D1 (de) 2011-03-10

Family

ID=32230466

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031225T Expired - Lifetime DE602004031225D1 (de) 2003-06-02 2004-05-25 3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks

Country Status (10)

Country Link
US (1) US6734206B1 (https=)
EP (1) EP1638936B1 (https=)
JP (1) JP2006526638A (https=)
AT (1) ATE496886T1 (https=)
AU (1) AU2004245492B2 (https=)
BR (1) BRPI0410926A (https=)
CA (1) CA2528010C (https=)
DE (1) DE602004031225D1 (https=)
ES (1) ES2358513T3 (https=)
WO (1) WO2004108670A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734201B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US7863318B2 (en) * 2005-11-03 2011-01-04 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8783923B2 (en) * 2010-03-18 2014-07-22 Chung Yuan Christian University Auto lamp structure

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
AU2211700A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
GEP20043203B (en) * 1999-12-22 2004-03-25 Pfizer Prod Inc EP4 Receptor Selective Agonists in the Treatment of Osteoporosis
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
JP4063468B2 (ja) 2000-02-22 2008-03-19 株式会社カネボウ化粧品 寒天被覆処理顔料およびメイクアップ化粧料
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
OA12533A (en) 2000-11-27 2006-06-05 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis.
JP4520738B2 (ja) * 2001-06-14 2010-08-11 アラーガン インコーポレイテッド 眼圧降下剤としての３、７、または３および７チアまたはオキサプロスタン酸誘導体
CA2451392A1 (en) * 2001-07-16 2003-01-30 F. Hoffmann-La Roche Ag Prostaglandin analogues as ep4 receptor agonists
CN100371322C (zh) 2001-07-16 2008-02-27 霍夫曼-拉罗奇有限公司 作为前列腺素类化合物激动剂的2-吡咯烷酮衍生物
EP2255829A3 (en) 2001-07-23 2012-03-28 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
WO2003077910A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists

Also Published As

Publication number Publication date
US6734206B1 (en) 2004-05-11
AU2004245492B2 (en) 2010-08-19
AU2004245492A1 (en) 2004-12-16
JP2006526638A (ja) 2006-11-24
CA2528010A1 (en) 2004-12-16
WO2004108670A1 (en) 2004-12-16
EP1638936A1 (en) 2006-03-29
CA2528010C (en) 2012-01-24
BRPI0410926A (pt) 2006-06-27
ES2358513T3 (es) 2011-05-11
ATE496886T1 (de) 2011-02-15
EP1638936B1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
DE50312946D1 (de) Difluormethyl thiazolyl carboxanilide
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
DE602004022633D1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
NO20070606L (no) Inhibitorer av IAP
TW200700070A (en) Enhanced bimatoprost ophthalmic solution
BR0310047A (pt) Análogos de 8-azaprostaglandina como agentes para diminuição de pressão intra-ocular
DE50306845D1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
TW200500339A (en) Pyrrolidine derivatives, and process for the preparation
NO20064282L (no) Morfolinforbindelser
CY1108808T1 (el) Ενωσεις μοτιλιδης
TW200630374A (en) Thiazolyldihydroindazoles
DE60234919D1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
DE602004031225D1 (de) 3-oxa-8-azaprostaglandinanaloga als mittel zum senken des augeninnendrucks
WO2006050861A3 (en) Statine derivatives for the treatment of alzheimer's disease
DE602005017815D1 (de) Behandlung von entzündlicher darmerkrankung
DE60330373D1 (de) Piperidinderivate als ccr5-inhibitoren
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины